Xalkori

Xalkori. It is a targeted therapy medication used to treat certain types of non-small cell lung cancer (NSCLC) and other malignancies. Developed by Pfizer, it functions as a tyrosine kinase inhibitor specifically designed to block the activity of abnormal proteins that drive cancer growth. Its approval marked a significant advancement in precision medicine, offering a treatment option for patients with specific genetic alterations.

Medical uses

Xalkori is indicated for the treatment of patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. It is also approved for the treatment of adults and pediatric patients 1 year and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. The identification of these specific biomarkers through diagnostic tests is critical for patient selection, exemplifying the principles of personalized medicine. Clinical trials, such as those published in the New England Journal of Medicine, demonstrated its efficacy in improving progression-free survival in these patient populations compared to traditional chemotherapy.

Adverse effects

Common adverse effects include visual disorders, nausea, diarrhea, swelling, constipation, and elevated liver enzymes. More serious potential side effects involve severe lung inflammation, liver toxicity, heart rhythm problems, and slow heart rate. Patients are monitored regularly with assessments including ECGs and blood tests for ALT and AST levels. Management strategies often involve dose interruptions, reductions, or discontinuation, as outlined in the prescribing information from the EMA and FDA.

Pharmacology

Xalkori is a small-molecule inhibitor of receptor tyrosine kinases including ALK, MET, and ROS1. It works by competitively binding to the ATP-binding site of these kinases, thereby inhibiting their phosphorylating activity and downstream signaling through pathways like the MAPK/ERK and PI3K-AKT-mTOR cascades. Following oral administration, it is absorbed with a time to peak concentration of 4 to 6 hours and is primarily metabolized by the CYP450 enzyme CYP3A4/5, necessitating caution with concomitant use of strong inhibitors or inducers like clarithromycin or rifampin.

History

The development of Xalkori originated from research into MET inhibitors at Pfizer's laboratories. Its potential for ALK-positive cancers was identified following the discovery of the EML4-ALK fusion oncogene in a subset of NSCLC patients by researchers in Japan. Pivotal clinical studies, including the PROFILE 1001 trial, led to its accelerated approval by the U.S. Food and Drug Administration in August 2011 for ALK-positive NSCLC, making it the first ALK inhibitor approved. Subsequent approvals followed from agencies worldwide, including the MHRA in the United Kingdom and the TGA in Australia.

Society and culture

Xalkori has been cited as a landmark example of a drug developed in tandem with a companion diagnostic, specifically the Vysis ALK Break Apart FISH Probe Kit from Abbott Laboratories. Its high cost has been a subject of discussion within healthcare systems and among payers like the NHS. The medication has been featured in media discussing advances in oncology, such as reports by The New York Times. Patient access programs have been established by Pfizer in various regions, and its development story is often highlighted in narratives about the success of translational research bridging genomic discoveries to clinical application.

Category:Antineoplastic drugs Category:Pfizer Category:World Health Organization essential medicines